1.58BMarket Cap-10465P/E (TTM)
7.670High7.495Low1.48MVolume7.610Open7.630Pre Close11.27MTurnover0.77%Turnover RatioLossP/E (Static)206.89MShares8.09052wk High-3.32P/B1.47BFloat Cap4.03052wk Low--Dividend TTM192.21MShs Float37.250Historical High--Div YieldTTM2.29%Amplitude0.600Historical Low7.598Avg Price1Lot Size
BioCryst Pharmaceuticals Stock Forum
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
No comment yet